Figure 3.

Urolithin M5 exhibited antiviral activities in PR8-infected mice. PR8-infected mice were administrated orally with 200 μL of 200 mg/kg/d urolithin M5, 65 mg/kg/day oseltamivir or 0.5% CMC for 6 consecutive days. (a) Body weights and (b) survival rate are shown. The efficacy of urolithin M5 and oseltamivir treatment on (c) lung index and (d) lung viral load of mice are shown. Six mice of each group were measured, and each assay was performed three times for confirmation. (* p 0.05, *** p 0.001).